Navigation Links
Celsion Corporation Reports First Quarter 2013 Financial Results and Provides Business Update

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.  Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the significant expense, time, and risk of failure of conducting clinical trials; HEAT Study data is subject to further verification and review by the HEAT Study Data Management Committee; the need for Celsion to evaluate its future development plans; termination of the Technology Development Contract or collaboration between Celsion and Hisun at any time; possible changes in cost and timing of development and testing, capital structure, financial condition, working capital needs and other financial items; possible acquisitions or licenses of other technologies, assets or businesses or the possible failure to make such acquisitions or licenses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Celsion's periodic reports filed with the Securities and Exchange Commission.  Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investor Contact Jeffrey W. Church
Senior Vice President – Corporate
Strategy and Investor Relations
609-482-2455  Celsion Corporation
Condensed Statements of Operations
(In thousands except per share amounts)
(Unaudited)Three Months Ended March 31,20132012Licensing revenue$



-Operating expenses: Research and development3,2034,693General

SOURCE Celsion Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Celsion Corporation to Hold First Quarter 2013 Financial Results Conference Call on Thursday, May 9, 2013
2. Celsion Corporation Provides Business Update
3. Todays Research on Celsion, Zogenix, Actavis, and Avanir Pharma
4. Celsion Corporation Announces $15 Million Registered Direct Offering
5. Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
6. ETEX Corporation announces extended Supply Agreement with Knee Creations, LLC
7. Verenium Corporation to Announce First Quarter 2013 Financial Results
8. EMCO High Voltage Corporation to Exhibit at 61st ASMS Conference on Mass Spectrometry and Allied Topics
9. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
10. Techne Corporation Releases Unaudited Third Quarter And Nine Month Fiscal Year 2013 Results
11. Street Named After EMCO High Voltage Corporation
Post Your Comments:
(Date:7/23/2014)... made great strides in saving China,s endangered national treasure, ... 65 giant panda reserves that have been established and ... 1596 pandas remain in the wild. , Breeding ... the panda by improving genetic diversity, avoid inbreeding and ... are these high-profile programs doing so far? , In ...
(Date:7/23/2014)... Vienna University of Technology and the Maria Curie-Skłodowska ... semiconductor crystals into a silicon nanowire. With this ... and multi-functional processing units can be accommodated on ... results will be published in the journal ... cornerstone of future chip technology, but the research ...
(Date:7/23/2014)... Ill. , July 23, 2014 /PRNewswire/ ... (SNA™) constructs as gene regulatory and immunotherapeutic ... has joined AuraSense Therapeutics, executive leadership ... 11. Prior to joining AuraSense ... and Chief Financial Officer of Cellular Dynamics ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 Last year, ... Systems , a leading global provider of data management ... with TrialMaster, a leading-edge system for electronic data capture ... of universal design and study execution tools added TrialMaster ... and much anticipated version of Transform for TrialMaster, is ...
Breaking Biology Technology:A crystal wedding in the nanocosmos 2AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3
... BVF Acquisition LLC (the "Purchaser"), an affiliate of Biotechnology Value ... to purchase all of the outstanding shares of Avigen, Inc. ... announced today that it has extended the expiration date for ... on Friday, March 6, 2009. The tender offer was previously ...
... Cord Blood America, Inc. (OTC Bulletin Board: CBAI), ... ( ) focused on bringing the life ... and internationally, today announced that Matthew Schissler, founder ... Gaskins, provided details of the Company,s special shareholder ...
... Declares 341st Consecutive Quarterly Dividend ABBOTT PARK, Ill., Feb. ... ABT ) today increased the company,s quarterly common dividend 11 ... consecutive year that Abbott has increased its dividend payout and ... since 1924. The cash dividend is payable May 15, ...
Cached Biology Technology:BVF Acquisition LLC Extends Avigen Tender Offer to March 6, 2009 2BVF Acquisition LLC Extends Avigen Tender Offer to March 6, 2009 3In Analyst Interview, Cord Blood America Provides Details of Special Shareholder Meeting 2
(Date:7/23/2014)... 23, 2014 BioCatch, the global ... today it has been named in Gartner,s Market Guide ... replaces Gartner,s well-known Magic Quadrant for Web Fraud Detection. ... one of several vendors to deliver passive biometric analysis ... a standard feature of at least 30% of one-stop ...
(Date:7/23/2014)... New Rochelle, NY -- The potential for clinical ... for transplant-based therapeutic strategies has previously been hindered ... the development of tumors. The ability to use ... for the treatment of heart disease, specifically acute ... Stem Cells and Development , a peer-reviewed ...
(Date:7/23/2014)... International Journal of Fuzzy Systems ( IJFS ), ... (TFSA). The cooperation will allow the journal to expand ... The International Journal of Fuzzy Systems is ... theory, design and application of fuzzy systems, soft computing ... hardware to software. Launched in 1999, the quarterly journal ...
Breaking Biology News(10 mins):BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 3
... WALTHAM, MA April 1, 2011 Avila ... drugs, today announced the publication of a scientific ... titled "The Resurgence of Covalent Drugs" ( , ... discusses the broad opportunities for covalent drugs and how ...
... never good for you, but washing that meal down with ... of Guelph study. Researcher Marie-Soleil Beaudoin has discovered not ... eating a high-fat meal, but that the spike doubles after ... to levels similar to those of people at risk for ...
... muscle strength. Not only can adults fight the battle ... Golden Years can be a time to get stronger, say experts ... exercise is a great way to increase lean muscle tissue and ... life," says Mark Peterson, Ph.D., a research fellow in the U-M ...
Cached Biology News:New opportunities for covalent drugs published by Avila scientists 2Got a craving for fast food? Skip the coffee, study says 2Older and stronger: Progressive resistance training can build muscle, increase strength as we age 2Older and stronger: Progressive resistance training can build muscle, increase strength as we age 3Older and stronger: Progressive resistance training can build muscle, increase strength as we age 4
Mouse monoclonal [X223] to Lamin B1 + B2 - Nuclear Envelope Marker ( Abpromise for all tested applications). entrezGeneID: 4001 SwissProtID: P20700...
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
... CELSR3 is an Orphan-U GPCR with an ... expressed during development at sites of active neurogenesis ... spinal cord, dorsal root ganglion, and eye. ESTs ... colon, heart/melanocyte/uterus, lung, nerve, and placenta libraries. ...
Biology Products: